Ipilimumab vs Pembrolizumab
Ipilimumab vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Ipilimumab and Pembrolizumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Pembrolizumab β 26 days.
Chemical Properties
Type: Ipilimumab β Antibody; Pembrolizumab β Antibody.